Array Inks Development Deal With Aisling-Backed Loxo
This article was originally published in The Pink Sheet Daily
Executive Summary
The two biotechs will team up to develop a preclinical oncology asset that could reach human testing as early as next year. The deal is one of many for the Colorado-based biopharma.
You may also be interested in...
Deals Of The Week Untangles The String Of Pearls
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
Third Rock Pumps $41 Million Into Global Blood Therapeutics
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.